CSBio CSBio

X
[{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Recursion Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Recursion Enters Into Global Licensing Agreement with Takeda to Develop TAK-733 in Hereditary Cancer Syndrome","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Takeda Pharmaceutical"},{"orgOrder":0,"company":"Teijin Pharma","sponsor":"TransThera Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Teijin Pharma and TransThera Biosciences Form Strategic R&D Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Teijin Pharma"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Taiho and Astex Extend Strategic Oncology Collaboration with MSD","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Taiho Pharmaceutical"},{"orgOrder":0,"company":"PeptiDream","sponsor":"RayzeBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PeptiDream and RayzeBio Expand Alliance on Peptide-Radiotherapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Peptide","graph2":"PeptiDream"},{"orgOrder":0,"company":"Ajinomoto Company","sponsor":"Exelixis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ajinomoto and Exelixis Enter Into a License Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Ajinomoto Company"},{"orgOrder":0,"company":"Alpha Fusion","sponsor":"Sumitomo Heavy Industries","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sumitomo Heavy Industries, Ltd. Invests in Alpha Fusion Inc., Developer of Astatine Based Radiopharmaceuticals for Targeted Alpha Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Alpha Fusion"},{"orgOrder":0,"company":"IPGaia","sponsor":"Duke-NUS Medical School","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Duke-NUS and Japan-based IPGaia Announce Partnership to Accelerate Innovation in Drug Discovery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"IPGaia"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Through the agreement, Duke-NUS will propose drug targets to IPG, which will, in turn, identify and develop lead compounds with the goal of licensing clinic-ready candidates to pharmaceutical companies.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Duke-NUS Medical School

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement November 07, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The financing will be used for the development of Alpha Fusion's pipeline including Astatine-211, an element belonging to halogens and has the property of emitting alpha particle.

            Lead Product(s): Astatine-211

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Sumitomo Heavy Industries

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Financing March 07, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            As part of the license agreement, Exelixis will have the right to use the AJICAP technology to support its aim of advancing multiple Antibody-drug Conjugates with the potential for higher efficacy and lower toxicity than currently available options.

            Lead Product(s): Antibody-drug Conjugate

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Exelixis

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 10, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Extension of the research collaboration term to allow for additional peptide-RI conjugate discovery and development programs. RayzeBio grants PeptiDream an option to attain development and commercialization rights in Japan to the joint peptide-RI programs.

            Lead Product(s): Peptide-radioisotope Conjugate

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Peptide

            Partner/Sponsor/Collaborator: RayzeBio

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership August 09, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Taiho Pharmaceutical announces that it and Astex Pharmaceuticals, both Otsuka group companies, have granted an exclusive license under their joint, small-molecule drug discovery program targeting SHP2 to Merck & Co.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Merck & Co

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Expanded Collaboration January 13, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Teijin Pharma and TransThera will establish a joint drug discovery collaboration of multiple drug targets with the immediate goal of acquiring compounds as candidates for new drug development based on the targets and compounds found by Teijin Pharma.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: TransThera Biosciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration December 18, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the agreement, Recursion obtains exclusive worldwide rights to develop and commercialize TAK-733.

            Lead Product(s): Tak-733

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Recursion Pharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement May 14, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY